QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kalbaugh, T. L. Articles by VanDongen, A. M. J. Search for Related Content PubMed PubMed Citation Articles by Kalbaugh, T. L. Articles by VanDongen, A. M. J.

Ligand-Binding Residues Integrate Affinity and Efficacy in the NMDA Receptor

Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina

The interaction of an agonist with its receptor can be characterized by two fundamental properties, affinity and efficacy. Affinity defines how tightly the agonist associates with its receptor, and efficacy measures the ability of the bound ligand to activate the receptor. Although affinity and efficacy are independent properties, the binding and activation processes that they describe are tightly coupled. This strong coupling has complicated the interpretation of concentration-response phenotypes caused by receptor mutations. We present an approach that quantifies the role of individual amino acids in defining affinity and efficacy. This method, which employs partial agonists and covalent modification of introduced cysteines, was applied to the ligand-binding sites of the NMDA receptor. Recent crystallographic structures for glutamate receptor ligand-binding cores allowed identification of residues that are either known or are predicted to be critical for ligand binding in the NR1 and NR2A subunit, respectively. Mutation of amino acids whose sidechains would directly coordinate bound ligands affected both agonist affinity and efficacy. In contrast, positions predicted to stabilize the closed-cleft conformation contributed only to agonist efficacy. The results provide a molecular basis for the tight coupling of agonist binding and receptor activation.

Address correspondence to: Antonius M. J. VanDongen, Department of Pharmacology and Cancer Biology, Duke University Medical Center, PO Box 3813, Durham, NC 27710. E-mail: vando005{at}mc.duke.edu

This article has been cited by other articles:

				M. L. Blanke and A. M. J. VanDongen Constitutive Activation of the N-Methyl-D-aspartate Receptor via Cleft-spanning Disulfide Bonds J. Biol. Chem., August 1, 2008; 283(31): 21519 - 21529. [Abstract] [Full Text] [PDF]

				M. L. Blanke and A. M. J. VanDongen The NR1 M3 Domain Mediates Allosteric Coupling in the N-Methyl-D-aspartate Receptor Mol. Pharmacol., August 1, 2008; 74(2): 454 - 465. [Abstract] [Full Text] [PDF]

				K. B. Hansen, R. P. Clausen, E. J. Bjerrum, C. Bechmann, J. R. Greenwood, C. Christensen, J. L. Kristensen, J. Egebjerg, and H. Brauner-Osborne Tweaking Agonist Efficacy at N-Methyl-D-aspartate Receptors by Site-Directed Mutagenesis Mol. Pharmacol., December 1, 2005; 68(6): 1510 - 1523. [Abstract] [Full Text] [PDF]

				P. E. Chen, M. T. Geballe, P. J. Stansfeld, A. R. Johnston, H. Yuan, A. L. Jacob, J. P. Snyder, S. F. Traynelis, and D. J. A. Wyllie Structural Features of the Glutamate Binding Site in Recombinant NR1/NR2A N-Methyl-D-aspartate Receptors Determined by Site-Directed Mutagenesis and Molecular Modeling Mol. Pharmacol., May 1, 2005; 67(5): 1470 - 1484. [Abstract] [Full Text] [PDF]